Rational corticosteroids administration and antibiotic treatment is key to managing cutaneous anthrax.
Clinical phenotype
Cutaneous anthrax
Treatment efficacy
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
17
02
2024
accepted:
12
09
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Anthrax is a global health concern, with cutaneous anthrax accounting for over 95% of cases and generally promising outcomes. Nonetheless, the absence of timely intervention can result in mortality rates of 10-40%. This research aims to explore the clinical presentations and phenotypic characteristics of cutaneous anthrax patients and evaluate the efficacy of various therapeutic approaches. A retrospective study was performed on 76 cutaneous anthrax patients identified at three hospitals from 2017 to 2022. Patients were categorized based on their hospital stay into two groups: those hospitalized for at least seven days and those for shorter durations. We assessed their clinical and phenotypic profiles, including symptoms, general health status, and laboratory findings, alongside treatment outcomes, focusing on corticosteroids therapy and antibiotic regimens. The study encompassed 76 diagnosed individuals, predominantly young adult males (78.9%). A significant gender disparity was noted. Hormonal treatment markedly improved edema regression in patients (P < 0.002), highlighting its therapeutic value. The impact of various antibiotic treatments on disease progression differed significantly based on corticosteroids treatment status, with specific combinations showing more effectiveness in non-corticosteroids-treated patients. The predominance of young male adults among cutaneous anthrax cases was observed, with corticosteroids treatment significantly reducing edema duration. In cases where corticosteroids therapy is not utilized, employing piperacillin-tazobactam alone or in combination with quinolones effectively shortens the illness duration, suggesting a tailored approach to treatment can enhance patient outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Anthrax is a global health concern, with cutaneous anthrax accounting for over 95% of cases and generally promising outcomes. Nonetheless, the absence of timely intervention can result in mortality rates of 10-40%. This research aims to explore the clinical presentations and phenotypic characteristics of cutaneous anthrax patients and evaluate the efficacy of various therapeutic approaches.
METHODS
METHODS
A retrospective study was performed on 76 cutaneous anthrax patients identified at three hospitals from 2017 to 2022. Patients were categorized based on their hospital stay into two groups: those hospitalized for at least seven days and those for shorter durations. We assessed their clinical and phenotypic profiles, including symptoms, general health status, and laboratory findings, alongside treatment outcomes, focusing on corticosteroids therapy and antibiotic regimens.
RESULTS
RESULTS
The study encompassed 76 diagnosed individuals, predominantly young adult males (78.9%). A significant gender disparity was noted. Hormonal treatment markedly improved edema regression in patients (P < 0.002), highlighting its therapeutic value. The impact of various antibiotic treatments on disease progression differed significantly based on corticosteroids treatment status, with specific combinations showing more effectiveness in non-corticosteroids-treated patients.
CONCLUSIONS
CONCLUSIONS
The predominance of young male adults among cutaneous anthrax cases was observed, with corticosteroids treatment significantly reducing edema duration. In cases where corticosteroids therapy is not utilized, employing piperacillin-tazobactam alone or in combination with quinolones effectively shortens the illness duration, suggesting a tailored approach to treatment can enhance patient outcomes.
Identifiants
pubmed: 39482596
doi: 10.1186/s12879-024-09922-9
pii: 10.1186/s12879-024-09922-9
doi:
Substances chimiques
Anti-Bacterial Agents
0
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1225Informations de copyright
© 2024. The Author(s).
Références
Alam ME, Kamal MM, Rahman M, Kabir A, Islam MS, Hassan J. Review of anthrax: a disease of farm animals. J Adv Vet Anim Res. 2022;9(2):323–34.
doi: 10.5455/javar.2022.i599
pubmed: 35891653
pmcid: 9298093
Leonard TE, Siratan E, Hartiadi LY, Crystalia AA. Insights into antimicrobial peptides in fighting anthrax: A review. Drug Dev Res. 2021;82(6):754–66.
doi: 10.1002/ddr.21803
pubmed: 33580543
Hendricks K, Person MK, Bradley JS, Mongkolrattanothai T, Hupert N, Eichacker P, et al. Clinical features of patients hospitalized for all routes of anthrax, 1880–2018: a systematic review. Clin Infect Dis. 2022;75(Supplement_3):S341–53.
doi: 10.1093/cid/ciac534
pubmed: 36251560
pmcid: 9649428
Yu X, Fang M, Wang S, Li Z, Cheng L, Liu Z, Zhang D, Dong D, Kou Z. Investigation on an outbreak of cutaneous anthrax in a county of Shandong Province, China, 2021. BMC Infect Dis. 2022;22(1):875.
doi: 10.1186/s12879-022-07802-8
pubmed: 36418992
pmcid: 9685941
Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266(5188):1202–8. PubMed PMID: 7973702.
doi: 10.1126/science.7973702
pubmed: 7973702
Rathjen NA, Shahbodaghi SD. Bioterrorism. Am Fam Physician. 2021;104(4):376–85.
pubmed: 34652097
Cross AR, Baldwin VM, Roy S, Essex-Lopresti AE, Prior JL, Harmer NJ. Zoonoses under our noses. Microbes Infect. 2019;21(1):10–9.
doi: 10.1016/j.micinf.2018.06.001
pubmed: 29913297
pmcid: 6386771
Caffes N, Hendricks K, Bradley JS, Twenhafel NA, Simard JM. Anthrax Meningoencephalitis and Intracranial Hemorrhage. Clin Infect Dis. 2022;75(Suppl 3):S451–8.
doi: 10.1093/cid/ciac521
pubmed: 36251558
pmcid: 9649421
Binney S, Person MK, Traxler RM, Cook R, Bower WA, Hendricks K. Algorithms for the Identification of Anthrax Meningitis During a Mass Casualty Event Based on a Systematic Review of Systemic Anthrax From 1880 Through 2018. Clin Infect Dis. 2022;75(Suppl 3):S468–77.
doi: 10.1093/cid/ciac546
pubmed: 36251554
pmcid: 9649431
Hendricks K, Person MK, Bradley JS, Mongkolrattanothai T, Hupert N, Eichacker P, Friedlander AM, Bower WA. Clinical Features of Patients Hospitalized for All Routes of Anthrax, 1880–2018: A Systematic Review. Clin Infect Dis. 2022;75(Suppl 3):S341–53.
doi: 10.1093/cid/ciac534
pubmed: 36251560
pmcid: 9649428
Sivakumar A, Kalimuthu A, Munisamy M. Cutaneous anthrax. JAMA Dermatol. 2022;158(9):1065.
doi: 10.1001/jamadermatol.2022.3216
pubmed: 35976633
Person MK, Cook R, Bradley JS, Hupert N, Bower WA, Hendricks K. Systematic Review of Hospital Treatment Outcomes for Naturally Acquired and Bioterrorism-Related Anthrax, 1880–2018. Clin Infect Dis. 2022;75(Supplement_3):S392–401.
doi: 10.1093/cid/ciac536
pubmed: 36251553
pmcid: 9649424
WHO; OIE; FAO. Anthrax in Humans and Animals. 4th ed. Geneva, Switzerland: World Health Organization; 2008.
Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis. 2002;8(2):222–5.
doi: 10.3201/eid0802.01-0521
pubmed: 11897081
pmcid: 2732453
Parker CM, Karchmer AW, Fisher MC, Muhammad KM, Yu PA. Safety of Antimicrobials for Postexposure Prophylaxis and Treatment of Anthrax: A Review. Clin Infect Dis. 2022;75(Suppl 3):S417–31.
doi: 10.1093/cid/ciac592
pubmed: 36251549
pmcid: 9649414
Dassanayake MK, Khoo TJ, An J. Antibiotic resistance modifying ability of phytoextracts in anthrax biological agent Bacillus anthracis and emerging superbugs: a review of synergistic mechanisms. Ann Clin Microbiol Antimicrob. 2021;20(1):79.
doi: 10.1186/s12941-021-00485-0
pubmed: 34856999
pmcid: 8641154
Doganay M, Dinc G, Kutmanova A, Baillie L. Human Anthrax: Update of the Diagnosis and Treatment. Diagnostics (Basel). 2023;13(6):1056.
doi: 10.3390/diagnostics13061056
pubmed: 36980364
Dutta TK, Sujatha S, Sahoo RK. Anthrax–update on diagnosis and management. J Assoc Physicians India. 2011;59:573–8.
pubmed: 22334971
Hart CA, Beeching NJ. A spotlight on anthrax. Clin Dermatol. 2002;20(4):365–75.
doi: 10.1016/S0738-081X(02)00256-0
pubmed: 12208624
Li S, Ma Q, Chen H, Liu Y, Yao G, Tang G, Wang D. Epidemiological Investigation and Etiological Analysis of a Cutaneous Anthrax Epidemic Caused by Butchering Sick Cattle in Guizhou. China Front Public Health. 2020;8:65.
doi: 10.3389/fpubh.2020.00065
pubmed: 32269982
Li S, Ma Q, Chen H, Wang D, Liu Y, Wei X, You L, Yao G, Tian K, Tang G. Genetic characterization of Bacillus anthracis in Guizhou Province, Southwest of China. BMC Microbiol. 2015Mar;31(15):77. https://doi.org/10.1186/s12866-015-0414-8.Erratum.In:BMCMicrobiol.2018;18(1):31 .
doi: 10.1186/s12866-015-0414-8.Erratum.In:BMCMicrobiol.2018;18(1):31
Liu DL, Wei JC, Chen QL, Guo XJ, Zhang EM, He L, Liang XD, Ma GZ, Zhou TC, Yin WW, Liu W, Liu K, Shi Y, Ji JJ, Zhang HJ, Ma L, Zhang FX, Zhang ZK, Zhou H, Yu HJ, Kan B, Xu JG, Liu F, Li W. Genetic source tracking of an anthrax outbreak in Shaanxi province, China. Infect Dis Poverty. 2017;6(1):14.
doi: 10.1186/s40249-016-0218-6
pubmed: 28093076
pmcid: 5240257
Mao L, Zhang E, Wang Z, Li Y, Zhou H, Liu X, Zhang H, Cai H, Liang X, Sun Y, Zhang Z, Li W, Yao W, Wei J. Phylogenetic Characteristics of Anthrax Outbreaks in Liaoning Province, China, 2001–2015. PLoS ONE. 2016;11(6): e0157496.
doi: 10.1371/journal.pone.0157496
pubmed: 27299730
pmcid: 4907462
Cavallo JD, et al. Antibiotic Susceptibilities of 96 Isolates of Bacillus anthracis Isolated in France between 1994 and 2000. Antimicrob Agents Chemother. 2002;46(7):2307–9.
doi: 10.1128/AAC.46.7.2307-2309.2002
pubmed: 12069996
pmcid: 127281
Popov SG, Popova TG, Grene E, Klotz F, Cardwell J, Bradburne C, Jama Y, Maland M, Wells J, Nalca A, Voss T, Bailey C. Alibek K Systemic cytokine response in murine anthrax. Cell Microbiol. 2004;6:225–33.
doi: 10.1046/j.1462-5822.2003.00358.x
pubmed: 14764106
Stearns-Kurosawa DJ, Lupu F, Taylor FB Jr, Kinasewitz G, Kurosawa S. Sepsis andpathophysiology of anthrax in a nonhuman primate model. Am J Pathol. 2006;169:433–44.
doi: 10.2353/ajpath.2006.051330
pubmed: 16877346
pmcid: 1698797
Hanna PC, Kochi S, Collier RJ. Biochemical and physiological changes induced by anthrax lathal toxin in J774 macrophage-like cells. Mol Biol Cell. 1992;3:1269–77.
doi: 10.1091/mbc.3.11.1269
pubmed: 1457831
pmcid: 275693
Shin S, Hur GH, Kim YB, Yeon GB, Park KJ, Park YM, Lee WS. Dehydroepiandrosterone and melatonin prevent Bacillus anthracis lethal toxin-induced TNF production in macrophages. Cell Biol Toxicol. 2000;16:165–74.
doi: 10.1023/A:1007606921569
pubmed: 11032360
Cordoba-Rodriguez R, Fang H, Lankford CS, Frucht DM. Anthrax lethal toxin rapidly activates caspase-1/ICE and induces extracellular release of interleukin (IL)-1beta and IL-18. J Biol Chem. 2004;279:20563–6.
doi: 10.1074/jbc.C300539200
pubmed: 15010463
Kalns J, Scruggs J, Millenbaugh N, Vivekananda J, Shealy D, Eggers J, et al. TNF receptor 1, IL-1 receptor, and iNOS genetic knockout mice are not protected from anthrax infection. Biochem Biophys Res Commun. 2002;292:41–4.
doi: 10.1006/bbrc.2002.6626
pubmed: 11890668
De Nicola AF, Meyer M, Guennoun R, Schumacher M, Hunt H, Belanoff J, de Kloet ER, Deniselle MCG. Insights into the therapeutic potential of glucocorticoid receptor modulators for neurodegenerative diseases. Int J Mol Sci. 2020;21:213. https://doi.org/10.3390/ijms21062137 .
doi: 10.3390/ijms21062137